HK1134690A1 - 子宮內膜生物標誌物 - Google Patents

子宮內膜生物標誌物

Info

Publication number
HK1134690A1
HK1134690A1 HK10101709.8A HK10101709A HK1134690A1 HK 1134690 A1 HK1134690 A1 HK 1134690A1 HK 10101709 A HK10101709 A HK 10101709A HK 1134690 A1 HK1134690 A1 HK 1134690A1
Authority
HK
Hong Kong
Prior art keywords
endometrial
biomarkers
endometrial biomarkers
Prior art date
Application number
HK10101709.8A
Other languages
English (en)
Inventor
W Michael Siu K
J Colgan Terence
D Romaschin Alexander
V De Souza Leroi
Original Assignee
Paul Walfish
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Walfish filed Critical Paul Walfish
Publication of HK1134690A1 publication Critical patent/HK1134690A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK10101709.8A 2006-10-27 2010-02-12 子宮內膜生物標誌物 HK1134690A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85478206P 2006-10-27 2006-10-27
PCT/CA2007/001935 WO2008049239A1 (en) 2006-10-27 2007-10-26 Endometrial biomarkers

Publications (1)

Publication Number Publication Date
HK1134690A1 true HK1134690A1 (zh) 2010-05-07

Family

ID=39324082

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10101709.8A HK1134690A1 (zh) 2006-10-27 2010-02-12 子宮內膜生物標誌物

Country Status (5)

Country Link
US (3) US8329399B2 (zh)
EP (1) EP2087152B1 (zh)
CA (1) CA2703795A1 (zh)
HK (1) HK1134690A1 (zh)
WO (1) WO2008049239A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
AU2004303448A1 (en) * 2003-12-23 2005-07-07 Mount Sinai Hospital Methods for detecting markers associated with endometrial disease or phase
CA2621363C (en) 2005-09-13 2015-07-07 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
CA2618163A1 (en) * 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
US9684001B2 (en) 2008-02-07 2017-06-20 Ranju Ralhan Biomarkers for head-and-neck cancers and precancers
CA2756570C (en) * 2009-04-17 2019-04-30 National Research Council Of Canada Peptide ligands for clusterin and uses thereof
DK2504363T3 (da) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
WO2012019300A1 (en) * 2010-08-10 2012-02-16 Siu K W Michael Endometrial cancer biomarkers and methods of identifying and using same
WO2013052108A2 (en) * 2011-10-03 2013-04-11 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of ovarian cancer
RU2647159C2 (ru) * 2011-12-30 2018-03-14 Конинклейке Филипс Н.В. Выбор клинического руководства по раку шейки матки
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
EP2787350A1 (en) * 2013-04-05 2014-10-08 Atlas Antibodies AB ASRGL1 in endometrial cancer
USD739549S1 (en) 2013-12-31 2015-09-22 Alamak Biosciences Incorporation Company Limited Tissue cell block
USD734483S1 (en) * 2013-12-31 2015-07-14 Alamak Biosciences Incorporation Company Limited Tissue cell block for cancer detection
DK3655778T3 (da) * 2017-07-21 2023-07-31 Fundacio Hospital Univ Vall D Hebron Institut De Recerca Agrin som en markør for endometriecancer
WO2024119119A1 (en) * 2022-12-02 2024-06-06 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
USRE32417E (en) 1979-10-29 1987-05-12 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4472371A (en) 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4311688A (en) 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4478818A (en) 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5317091A (en) 1991-02-27 1994-05-31 Akzo N.V. Technetium-99m labeling of proteins
AU1159601A (en) * 1999-11-03 2001-05-14 Metris Therapeutics Limited Agents implicated in endometriosis
AU2110301A (en) * 1999-12-20 2001-07-03 Schepens Eye Research Institute, The Anti-muc5b antibody and assay of muc5b mucin in mucus and other bodily secretions
WO2002009573A2 (en) * 2000-07-31 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of endometrial cancer
AU2002213704A1 (en) 2000-10-27 2002-05-06 Mount Sinai Hospital Method for detecting ovarian cancer based on human kallikrein 6 (HK6)
AU2002213720A1 (en) 2000-11-01 2002-05-15 Mount Sinai Hospital Detection of ovarian cancer
CA2448355A1 (en) 2001-05-25 2002-12-05 Mount Sinai Hospital Method of detecting and monitoring prostate and ovarian cancers
US20050176002A1 (en) 2001-10-16 2005-08-11 Mount Sinai Hospital Methods for detecting ovarian cancer
KR101166214B1 (ko) * 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
CA2481093A1 (en) 2002-04-04 2003-10-16 Mount Sinai Hospital Methods for detecting ovarian cancer
US20060073525A1 (en) 2002-08-28 2006-04-06 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
AU2003266038A1 (en) 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
CA2499261A1 (en) 2002-09-26 2004-04-08 Mount Sinai Hospital Methods for detecting endocrine cancer
US20060134120A1 (en) 2003-02-26 2006-06-22 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
US7659062B2 (en) * 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
AU2004303448A1 (en) 2003-12-23 2005-07-07 Mount Sinai Hospital Methods for detecting markers associated with endometrial disease or phase
US20060008876A1 (en) * 2004-07-07 2006-01-12 Shami A S E ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis
CA2597271A1 (en) * 2005-02-16 2006-08-24 Dana-Farber Cancer Institute Methods of detecting ovarian cancer
WO2006099126A2 (en) * 2005-03-11 2006-09-21 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
US20110038845A1 (en) 2005-05-05 2011-02-17 Mohamed Bedaiwy Diagnosis and treatment for endometriosis
EP1846768A4 (en) 2006-01-04 2009-04-08 Fujirebio America Inc USE OF HE4 AND OTHER BIOCHEMICAL MARKERS IN THE EVALUATION OF OVARIAN CANCERS

Also Published As

Publication number Publication date
US20130102004A1 (en) 2013-04-25
EP2087152B1 (en) 2015-03-11
US20100172838A1 (en) 2010-07-08
US9863005B2 (en) 2018-01-09
EP2087152A1 (en) 2009-08-12
EP2087152A4 (en) 2010-10-27
CA2703795A1 (en) 2008-05-02
WO2008049239A1 (en) 2008-05-02
US8329399B2 (en) 2012-12-11
US20150045255A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
HK1134690A1 (zh) 子宮內膜生物標誌物
EP2089722A4 (en) BIOMARKERS
GB0719792D0 (en) Cancer biomarkers
GB0610828D0 (en) New use for cannabinoid
EP2162552A4 (en) BIOMARKERS FOR MELANOMES
GB0709295D0 (en) New Zealander
ZA200907027B (en) Biomarkers for multiple sclerosis
EP2265642A4 (en) BIOMARKERS
ZA200808172B (en) Tea-flavored beer
EP1883343A4 (en) DETECTION BY BIOMARKERS
GB2436623B (en) Microtome
IL198735A0 (en) Pesticide biomarker
HK1109502A1 (en) Battary can
EP2263086A4 (en) BIOMARKERS
IL173251A0 (en) Multi purpose probe
GB0618127D0 (en) Biomarker
IL187675A0 (en) Light-emitting biomarker
GB0818660D0 (en) Biomarkers
GB0807214D0 (en) Biomarkers
GB0511302D0 (en) Biomarkers
EP2265641A4 (en) BIOMARKERS
GB0612669D0 (en) Biomarkers for preeclampsia
GB0821912D0 (en) Biomarkers
GB0818658D0 (en) Biomarkers
DE602007003815D1 (en) Men

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF THE INVENTOR FROM MICHAEL K. W. SIU TO K. W.MICHAEL SIU

Effective date: 20160225

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201023